Longevity logo

Endobronchial Ultrasound Biopsy Market Size and Forecast 2025–2033

Minimally Invasive Diagnostics Reshaping the Future of Lung Disease Detection

By Renub ResearchPublished about 10 hours ago 5 min read

Introduction: A New Era in Pulmonary Diagnostics

The global healthcare industry is witnessing a decisive shift toward minimally invasive diagnostic techniques, particularly in oncology and respiratory medicine. Among the most transformative technologies driving this change is endobronchial ultrasound (EBUS)–guided biopsy, a procedure that allows clinicians to diagnose and stage lung diseases with exceptional accuracy and reduced patient risk.

According to Renub Research–based estimates, the Endobronchial Ultrasound Biopsy Market is expected to grow from US$ 820 million in 2024 to US$ 1,275.36 million by 2033, expanding at a compound annual growth rate (CAGR) of 5.03% from 2025 to 2033. This steady growth is supported by rising lung cancer incidence, increasing prevalence of chronic respiratory diseases, and rapid adoption of minimally invasive diagnostic procedures across hospitals and specialty clinics worldwide.

Download Free Sample Report

Market Overview: Understanding Endobronchial Ultrasound Biopsy (EBUS)

Endobronchial ultrasound biopsy is an advanced bronchoscopic procedure that combines real-time ultrasound imaging with needle aspiration to obtain tissue samples from lymph nodes and lung lesions. It is primarily used in diagnosing and staging non-small cell lung cancer (NSCLC) but is increasingly applied to infectious diseases, sarcoidosis, and other pulmonary conditions.

Unlike traditional surgical biopsies, EBUS is performed through the airway, eliminating the need for open surgery. This results in shorter hospital stays, faster recovery, fewer complications, and lower overall costs. Its ability to reach peripheral and hard-to-access lesions has made it a gold standard for mediastinal staging in lung cancer.

Technological advancements—such as high-resolution imaging, real-time needle guidance, and improved ultrasound processors—have further enhanced diagnostic accuracy. Leading medical device companies, including Olympus Corporation, Boston Scientific, Cook Medical, Medtronic, GE Healthcare, and FUJIFILM, are continuously investing in product innovation to improve clinical outcomes and procedural efficiency.

Key Growth Drivers of the Endobronchial Ultrasound Biopsy Market

1. Rising Incidence of Lung Cancer

Lung cancer remains one of the deadliest cancers worldwide, and early diagnosis is critical to improving survival rates. EBUS-guided biopsy has become a preferred diagnostic approach because it enables accurate staging without the need for invasive surgical interventions.

For instance, the American Cancer Society projects 226,650 new lung cancer cases in the United States in 2025, with approximately 124,730 deaths. As global lung cancer incidence continues to rise due to smoking, air pollution, and occupational hazards, the demand for efficient and accurate diagnostic tools like EBUS is accelerating.

2. Shift Toward Minimally Invasive Procedures

Healthcare systems worldwide are prioritizing patient safety, faster recovery, and cost-effectiveness. Compared to conventional mediastinoscopy or surgical biopsy, EBUS offers a safer, faster, and less traumatic alternative.

This shift is not limited to developed markets. Emerging economies are also embracing minimally invasive diagnostics as healthcare infrastructure improves and patient awareness increases. The preference for procedures that reduce hospital stays and postoperative complications is a major factor propelling the EBUS biopsy market forward.

3. Growing Adoption in Emerging Markets

Developing countries are investing heavily in healthcare modernization. Hospitals and diagnostic centers in Asia-Pacific, the Middle East, and Latin America are increasingly equipped with advanced imaging and endoscopic systems.

Government initiatives aimed at improving early cancer detection and respiratory disease management are further boosting demand. As training programs expand and medical professionals gain expertise in EBUS techniques, market penetration in these regions is expected to rise steadily throughout the forecast period.

Challenges Facing the Endobronchial Ultrasound Biopsy Market

1. High Equipment and Maintenance Costs

EBUS systems require substantial upfront investment, including ultrasound processors, scopes, specialized needles, and imaging accessories. Maintenance, upgrades, and consumables add to ongoing costs, making adoption difficult for smaller hospitals and clinics.

This financial barrier is particularly challenging in low-resource settings, where healthcare budgets are limited. As a result, EBUS adoption remains concentrated in larger urban hospitals and well-funded specialty centers.

2. Limited Availability of Trained Professionals

EBUS procedures require skilled pulmonologists and technicians who are trained in both ultrasound interpretation and bronchoscopic navigation. However, there is a global shortage of trained personnel, especially in rural and emerging markets.

Without adequate expertise, diagnostic accuracy can decline, limiting the procedure’s effectiveness and slowing market expansion. Addressing this gap through training programs and digital learning platforms will be critical for future growth.

Regional Market Insights

United States Endobronchial Ultrasound Biopsy Market

The U.S. remains a global leader in the adoption of EBUS biopsy, supported by advanced healthcare infrastructure, high cancer awareness, and strong reimbursement policies. The rising incidence of lung cancer and the push toward minimally invasive diagnostics have made EBUS an essential tool in pulmonology departments.

With continuous technological innovation and FDA approvals for new biopsy systems, the U.S. market is expected to maintain steady growth throughout the forecast period.

United Kingdom Endobronchial Ultrasound Biopsy Market

In the UK, EBUS adoption is supported by the National Health Service (NHS) and its focus on early cancer detection. Hospitals increasingly rely on EBUS for accurate staging of lung cancer, reducing the need for surgical biopsies.

However, high equipment costs and the need for specialized training remain limiting factors. Despite these challenges, rising awareness and technological advancements are expected to drive continued market expansion.

India Endobronchial Ultrasound Biopsy Market

India represents one of the fastest-growing markets for EBUS biopsy due to increasing lung disease burden, improving healthcare access, and expanding private hospital networks. Urban tertiary care centers are rapidly adopting EBUS for cancer and infection diagnostics.

Government programs focused on strengthening diagnostic capabilities and early detection are expected to further boost demand, although cost and training barriers still limit widespread adoption in rural areas.

Saudi Arabia Endobronchial Ultrasound Biopsy Market

Saudi Arabia’s healthcare transformation initiatives under Vision 2030 are accelerating the adoption of advanced diagnostic technologies. Rising respiratory disease prevalence and increased government investment in modern hospitals are supporting EBUS market growth.

The country is witnessing expanding use of minimally invasive diagnostic procedures, although the need for skilled professionals and high system costs remains a challenge.

Recent Developments in the EBUS Biopsy Industry

The industry continues to evolve with strong innovation momentum:

October 2024: GE Healthcare announced expansion of its medical imaging manufacturing facility in Wisconsin to meet rising global demand for ultrasound systems.

September 2024: FUJIFILM Healthcare Europe introduced enhanced compatibility of its ARIETTA 750 FF ENDO ultrasound system with linear bronchoscopes, improving image clarity and diagnostic confidence.

October 2023: Praxis received FDA approval for its EndoCore EBUS-TBNA biopsy device, designed to enhance sampling accuracy and procedural efficiency.

These developments highlight strong manufacturer commitment to advancing EBUS technology and expanding its clinical utility.

Market Segmentation Overview

By Product

EBUS Scopes

EBUS Needles

Ultrasound Processors and Imaging Systems

Accessories

By Application

Cancer Diagnostic

Infection Diagnostic

Others

By End Use

Hospitals

Ambulatory Surgical Centers (ASCs)

Specialty Clinics

By Region

North America: United States, Canada

Europe: UK, Germany, France, Italy, Spain, Belgium, Netherlands, Turkey

Asia-Pacific: China, Japan, India, Australia, South Korea, Southeast Asia

Latin America: Brazil, Mexico, Argentina

Middle East & Africa: Saudi Arabia, UAE, South Africa

Competitive Landscape

Key players shaping the global EBUS biopsy market include:

GE Healthcare

Siemens Healthcare Private Limited

Koninklijke Philips N.V.

Boston Scientific Corporation

Olympus Corporation

Cook Group Incorporated

FUJIFILM Holdings Corporation

Medi-Globe Technologies GmbH

These companies compete through product innovation, geographic expansion, partnerships, and regulatory approvals, strengthening their global presence and expanding access to advanced diagnostic solutions.

Final Thoughts: A Market Poised for Sustainable Growth

The Endobronchial Ultrasound Biopsy Market stands at the intersection of technological innovation and urgent clinical need. As lung cancer and respiratory diseases continue to rise globally, the demand for safe, accurate, and minimally invasive diagnostic solutions will only intensify.

With steady technological improvements, expanding healthcare infrastructure in emerging markets, and growing physician expertise, EBUS-guided biopsy is set to become an indispensable tool in pulmonary diagnostics. While challenges such as high costs and workforce shortages persist, the market’s long-term outlook remains positive.

healthindustry

About the Creator

Renub Research

Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. Call Us : +1-478-202-3244

Reader insights

Be the first to share your insights about this piece.

How does it work?

Add your insights

Comments

There are no comments for this story

Be the first to respond and start the conversation.

Sign in to comment

    Find us on social media

    Miscellaneous links

    • Explore
    • Contact
    • Privacy Policy
    • Terms of Use
    • Support

    © 2026 Creatd, Inc. All Rights Reserved.